Gain Therapeutics
GANXGain Therapeutics is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for central nervous system disorders, lysosomal storage disorders, and metabolic diseases.
Table of contents
Earnings
Next report
Aug 11, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Gain Therapeutics is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for central nervous system disorders, lysosomal storage disorders, and metabolic diseases. The company utilizes its proprietary Magellan™ computational platform to identify allosteric binding sites on proteins, enabling the discovery of drugs that treat the underlying causes of disease through functional and conformational modulation.
Gain Therapeutics is a pioneer in allosteric drug discovery, leveraging a proprietary computational platform to target previously undruggable protein sites.
Questions, answered.
- What is Gain Therapeutics's market cap?
- Gain Therapeutics (GANX) has a market capitalization of $79.3M and trades on NASDAQ.
- Who are Gain Therapeutics's competitors?
- Gain Therapeutics's key competitors include Schrödinger, Inc., Denali Therapeutics Inc., Prevail Therapeutics, and others. These companies compete in similar markets and product categories.
- What subsidiaries does Gain Therapeutics have?
- Gain Therapeutics's subsidiaries include Gain Therapeutics SA.
- Where is Gain Therapeutics headquartered?
- Gain Therapeutics is headquartered in United States of America and employs approximately 32 people. It has been publicly traded since 2021.